| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | RECRUITING | PHASE2, PHASE3 | 2024-05-14 | 2029-05 | 2029-05 |
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | RECRUITING | PHASE2 | 2021-09-23 | 2026-12 | 2025-09 |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING | PHASE1, PHASE2 | 2019-12-10 | 2027-05-12 | 2026-10-30 |
| NCT03815396 | Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency | COMPLETED | PHASE1 | 2019-07-19 | 2022-08-18 | 2022-08-18 |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | TERMINATED | PHASE1 | 2019-01-30 | 2024-10-03 | 2024-10-03 |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas | RECRUITING | PHASE1 | 2018-10-10 | 2026-12 | 2026-06 |